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Deletions of chromosome 1p36 affect approximately 1 in 5,000 newborns and are associated with developmental delay, intellectual
disability, and defects involving the brain, eye, ear, heart, and kidney. Arginine-glutamic acid dipeptide repeats (RERE) is located in
the proximal 1p36 critical region. RERE is a widely-expressed nuclear receptor coregulator that positively regulates retinoic acid
signaling. Animal models suggest that RERE deficiency might contribute to many of the structural and developmental birth defects
and medical problems seen in individuals with 1p36 deletion syndrome, although human evidence supporting this role has been lack-
ing. In this report, we describe ten individuals with intellectual disability, developmental delay, and/or autism spectrum disorder who
carry rare and putatively damaging changes in RERE. In all cases in which both parental DNA samples were available, these changes were
found to be de novo. Associated features that were recurrently seen in these individuals included hypotonia, seizures, behavioral prob-
lems, structural CNS anomalies, ophthalmologic anomalies, congenital heart defects, and genitourinary abnormalities. The spectrum of
defects documented in these individuals is similar to that of a cohort of 31 individuals with isolated 1p36 deletions that include RERE
and are recapitulated in RERE-deficient zebrafish and mice. Taken together, our findings suggest that mutations in RERE cause a genetic
syndrome and that haploinsufficiency of RERE might be sufficient to cause many of the phenotypes associated with proximal 1p36
deletions.Deletions of chromosome 1p36 constitute the most com-
mon group of terminal deletions in humans—affecting
approximately 1 in 5,000 newborns—and are recognized
as an important cause of intellectual disability.1–3 Addi-
tional phenotypes that characterize the 1p36 deletion
syndrome (MIM: 607872) include developmental delay,
seizures, brain anomalies, vision problems, hearing loss,
orofacial clefting, congenital heart defects, cardiomyopa-
thy, renal anomalies, short stature, and a recognizable
constellation of dysmorphic features—microbrachyce-
phaly; large, late-closing anterior fontanel; posteriorly
rotated, low-set, abnormally shaped ears; straight eye-
brows; deep-set eyes; epicanthal folds; midface hypoplasia;
a wide and depressed nasal bridge; a long philtrum; and a
pointed chin.4–6 By analyzing the clinical presentations
of individuals with terminal 1p36 deletions, Wu et al.
determined that haploinsufficiency of genes located distal
to marker D1S2870 (chr1:6,289,764–6,289,973; hg19) was
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region.8
Subsequently, Kang et al. delineated a non-overlapping
proximal 1p36 critical region (chr1:8,395,179–11,362,893;
hg19) which, when deleted, was associated with a similar
constellation of phenotypes—intellectual disability, devel-
opmental delay, vision problems, hearing loss, orofacial
clefting, congenital heart defects, cardiomyopathy, and
short stature.9 However, these individuals had distinctive
facial features—frontal andparietal bossing, low-set, posteri-
orly-rotated ears, epicanthal folds, anteverted nares, broad
eyebrows, and hirsutism.
Animal models have implicated several genes located in
the distal and proximal 1p36 critical regions as potential
contributors to the neurodevelopmental and structural
birth defects associated with the 1p36 deletion syn-
drome.8 However, human evidence supporting the role
of these genes in the development of specific phenotypes
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Table 1. RERE Sequence Changes Identified in Subjects 1–10
Subject
No. Sequence Changes in REREa PolyPhen-2 SIFT MutationTaster
Alleles in Exome
Variant Server
Alleles in ExAC
Browser
1 c.3466 G>A, p.Gly1156Arg probably
damaging
damaging disease causing none 2/66,082 European;
2/120,478 totalb
2 c.4313_4318dupTCCACC,
p.Leu1438_His1439dup
NA NA polymorphism none none
3 c.3785C>G, p.Pro1262Arg probably
damaging
damaging disease causing none none
4 c.4293C>G, p.His1431Gln probably
damaging
damaging disease causing none none
5 c.4293C>A, p.His1431Gln probably
damaging
damaging disease causing none none
6 c.3122delC, p.Pro1041Lysfs*40 NA NA disease causing none none
7 c.1411G>A, p.Val471Ile possibly
damaging
tolerated disease causing 1, African American none
8 c.1104delA, p.Leu369Cysfs*16 NA NA NAc none none
9 c.2249_2270dup p.Thr758Serfs*36 NA NA disease causing none none
10d c.2278 C>T, p.Gln760* NA NA disease causing none none
NA, not applicable.
aBased on RERE transcript variant 1 [RefSeq: NM_012102.3].
bAlleles found only in the heterozygous state.
cChange affects the last nucleotide of an exon.
dSubject 10 was previously reported by Krumm et al. as subject 11654.p1.18caused by haploinsufficiency of specific genes makes it
difficult for physicians to provide prognostic information
to families and to generate individualized care plans for
their patients solely on the basis of the location and extent
of their 1p36 deletions.
Arginine-glutamic acid dipeptide repeats (RERE [MIM:
605226]) is located in the proximal 1p36 critical region.8,9
RERE encodes awidely-expressednuclear receptor coregula-
tor that positively regulates retinoic acid signaling.10–12
Data available from the Exome Aggregation Consortium
(ExAC) Browser suggests that RERE has a high probability
of loss-of-function intolerance (pLI ¼ 1.0) given that 47.5
loss-of-function variants were expected based on gene size
andGCcontent but only threewere observed.Data fromze-
brafish and mouse models suggest that haploinsufficiency
of RERE might contribute to the intellectual disability,
developmental delay, structural brain anomalies, vision
problems, hearing loss, congenital heart defects, cardiomy-
opathy, and renal anomalies seen in individuals with 1p36
deletions.13–17However, the exact role that REREdeficiency
plays in 1p36 deletion syndrome, and more generally in
human disease, remains unclear.
Here, we describe ten individuals with neurodevelop-
mental phenotypes and congenital anomalies who carry
rare, putatively deleterious, sequence changes in RERE.
Clinical data were obtained through written informed
consent. In all cases, the procedures followed were in
accordance with the ethical standards of the respective
institution’s committee on human research and were in
keeping with national standards. RERE sequence changes
were identified in nine of these individuals (subjects964 The American Journal of Human Genetics 98, 963–970, May 5, 21–9) by clinically-based exome sequencing performed in
CLIA- or ISO15189-certified laboratories and confirmed
by Sanger sequencing. Changes in subject 10 were identi-
fied by the Simons Foundation Autism Research Initiative
(SFARI) and reported in SFARI Base—a central database of
clinical and genetic information about families affected
by autism and other neurodevelopmental disorders. In all
cases where parental DNA samples were available, these
changes were found to be de novo. The clinical pheno-
types of these individuals and a description of their RERE
sequence changes—including in silico prediction of effects
on protein function via PolyPhen-2, SIFT, and Muta-
tionTaster and allele frequencies in control populations re-
ported in the NHLBI Exome Variant Server and the ExAC
Browser—are summarized below and in Table 1, Tables S1
and S2, Figure 1, and the Supplemental Note.
Subject 1 is a 3-year-old male of European descent who
carries a de novo c.3466G>A, p.Gly1156Arg missense
change in RERE (GenBank: NM_012102.3). He was noted
to have intrauterine growth retardation, was born prema-
turely at 35 weeks of gestation, and was small for gestation
age with a birth weight of 1.64 kg (<3rd percentile). Multi-
ple regions of infarction were found in the placenta. His
clinical features include global developmental delay, mild
spastic quadriparesis, dysarthric speech, swallowing diffi-
culties, bilateral optic colobomas, optic nerve hypoplasia,
unilateral microphthalmia, anisometropia, mild senso-
rineural hearing loss, micrognathia, a ventricular septal
defect (VSD), a patent foramen ovale, hypospadias
with penile chordee, and gastresophageal reflux disease
(GERD). A brain MRI obtained at 7 months of age revealed016
Figure 1. Molecular Changes and
Selected Clinical Findings for Individuals
with Putatively Deleterious Changes
in RERE
(A) The predicted locations of domains
within RERE are presented along with the
locations of the RERE changes seen in sub-
jects 1–10.
(B) Craniofacial changes noted in subjects.
Subject 1, at 3 years of age, presents with
bilateral optic colobomas, unilateral mi-
cropthalmia, low-set ears, and microgna-
thia. Subject 2, at 11 months of age,
presents with a unilateral iris coloboma
and simple ears. Subject 4, at 9 years of
age, presents with deep-set eyes, epican-
thal folds, and abnormal ears.
(C) Sagital (Sag) and axial brain MRI scans
of subjects 1, 2, and 4 demonstrating char-
acteristic findings. Subject 1, at 7 months
of age, had a thin corpus callosum (red ar-
row), a small anterior vermis, a small pons
with a ventral cleft at the ponto-medul-
lary junction, delayed myelination, and
severely decreased white matter volume.
Subject 2, at 4 months of age, had a thin
corpus callosum, ventriculomegaly (green
arrow), incompletely folded hippocampi,
and severely diminished white matter vol-
ume. Subject 4, at 1 year and 2 months of
age, had a thin corpus callosum, a dimin-
ished cerebellar vermis with a deep fissures
(blue arrow), and significantly diminished
white matter volume. For comparison,
we have shown a mid-sagittal T1-weighted
image showing a normal sized corpus
callosum and intact cerebellar vermis
and an axial T2-weighted image showing
normal sized ventricles without increased
extra-axial space.a thin corpus callosum, small anterior vermis, small pons
with a ventral cleft at the ponto-medullary junction, de-
layed myelination, and severely decreased white matter
volume (Figure 1).
Subject2 is a15-month-oldmaleofEuropeandescentwho
carries a de novo c.4313_4318dupTCCACC, p.Leu1438_
His1439dup change in RERE. This change results in the
addition of a leucine and histidine to an already histidine-
rich compositional bias region of RERE (UniProt: Q9P2R6).
This type of change is not amenable to evaluation by
PolyPhen-2or SIFT, andMutationTaster predicts this change
to be a polymorphism. However, this duplication—like the
amino acid change in subject 1—is found in a conserved
region of the atrophin domain of RERE. He was also found
to have a de novo c.4211G>A, p.Arg1404His (GenBank:
NM_001252100.1) change in kinesin family member 21B
(KIF21B [MIM: 608322]) and a de novo c.1433C>T,
p.Pro478Leu (GenBank: NM_170744.4) change in unc-5The American Journal of Humanetrin receptor B (UNC5B [MIM:
607870]). Both of these changes were
predicted to be probably damaging by
PolyPhen-2, damaging by SIFT, anddisease causing by MutationTaster. KIF21B encodes a mem-
ber of the kinesin family of proteins that acts as a plus-end-
directed microtubule motor, participating in transport of
cellular cargo in neurons as well as in other cell types.19 Var-
iants in KIF21B have been associated withmultiple sclerosis
and ankylosing spondylitis in genome-wide association
studies.20,21 The UNC5 family of proteins plays a critical
role in anumber of cellular processes, including axonal guid-
ance, angiogenesis, and apoptosis. However, mutations in
UNC5B have not been associated with a genetic disorder in
humans.22
Subject 2 was born prematurely at 30 weeks and 6 days
of gestation via C-section for symmetric intrauterine
growth retardation and fetal distress. His birth weight
was 0.94 kg (~3rd percentile). His clinical features include
developmental delay, post-natal growth retardation, short
stature with a height of 64 cm at 15 months (<1st percen-
tile), microcephaly with an occipital frontal circumferencen Genetics 98, 963–970, May 5, 2016 965
(OFC) of 42.5 cm at 15 months (<1st percentile), a unilat-
eral iris coloboma, choanal atresia, a VSD, a patent ductus
arteriosus, unilateral multicystic kidney, and cryptorchi-
dism. A brain MRI obtained at 4 months revealed a thin
corpus callosum, ventriculomegaly, incompletely folded
hippocampi, and severely diminished white matter vol-
ume. This subject was initially presumed to have CHARGE
syndrome. However, CHD7 sequencing and deletion and
duplication analysis revealed no pathologic variants.
Subject 3 is a 2-year-old Hispanic male who carries a
de novo c.3785C>G, p.Pro1262Arg missense change in
RERE that was found to be probably damaging by Poly-
Phen-2, damaging by SIFT, and disease causing by Muta-
tionTaster. Pregnancy was complicated by polyhydram-
nios secondary to duodenal atresia. His other clinical
features include post-natal growth retardation with a
weight of 10.3 kb (1st percentile), a height of 82 cm (2nd
percentile), and an OFC of 46.4 cm (4th percentile) at
2 years and 4months of age, developmental delay, hypoto-
nia, staring spells, dysmorphic features, unilateral Peter
anomaly, bilateral iris abnormalities, a VSD, bilateral
hydronephrosis with grade 2–4 vesicoureteral reflux, an
annular pancreas, and syndactyly. A brain MRI obtained
at 1 year and 6 months showed a thin corpus callosum,
deep primary fissure of the cerebellar vermis, ventriculo-
megaly, and severely diminished white matter volume.
Subject 4 is a 9-year-old female of European descent who
carries a de novo c.4293C>G, p.His1431Gln missense
change in RERE that was found to be probably damaging
by PolyPhen-2, damaging by SIFT, and disease causing by
MutationTaster. She was also found to be mosaic for a de
novo c.2464G>A, p.Gly822Ser (GenBank: NM_021007.2)
change in sodium channel, voltage-gated, type II alpha
subunit (SCN2A [MIM: 182390]). This variant is present
in 14/95 reads for 14.7%mosaicismwith a 95% confidence
interval of 8.3%–23.5%. This SCN2A change is predicted
to be probably damaging by PolyPhen-2, damaging by
SIFT, and disease causing by MutationTaster. Mutations
in SCN2A have been implicated in two autosomal-domi-
nant disorders: epileptic encephalopathy, early infantile,
11 (MIM: 613721) and seizures, benign familial infantile,
3 (MIM: 607745). Her clinical features included hypotonia,
moderate intellectual disability, severe behavioral issues
and seizures, dysmorphic features, GERD, developmental
hip dysplasia, and severe vesicoureteral reflux requiring
surgery. A brain MRI obtained at 1 year and 2 months
showed a thin corpus callosum, a diminished cerebellar
vermis with deep fissures, and significantly diminished
white matter volume—findings not reported in prior
studies of SCN2A.23,24
Subject 5 is a 12-year, 8-month-old Dutchmale (reported
previously by Bosch et al. as patient 22) with a de novo
c.4293C>A change in RERE that results in the same amino
acid change, p.His1431Gln, caused by the c.4293C>G
change documented in subject 4.25 His clinical features
include severe developmental delay, seizures, feeding prob-
lems, blepharophimosis, strabismus, bilateral optic atro-966 The American Journal of Human Genetics 98, 963–970, May 5, 2phy, cortical visual impairment, dysmorphic features,
GERD, and pyloric hypertrophy requiring surgical inter-
vention. A brain MRI obtained at 3 years and 6 months
of age showed an abnormal corpus callosum with blunting
of the rostrum, mild tomoderate ventriculomegaly, a small
cerebellar vermis, and globally diminished white matter
volume.
Subject 6 is a 6-year-old adopted female of mixed
European and Hispanic descent with a c.3122delC,
p.Pro1041Lysfs*40 frameshift change in RERE. Parental
DNA is not available. Given that this change occurs in
the 17th of 21 RERE coding exons, it might trigger
nonsense-mediated mRNA decay. Pregnancy and birth his-
tory are limited, but there was reported alcohol use during
the pregnancy. Her family history is positive for intellec-
tual disability and mental illness in her biological mother
and intellectual disability in both of her maternal grand-
parents and a maternal half-uncle. Her clinical features
include developmental delay, hypotonia, behavior prob-
lems, dysmorphic features, lumbar lordosis, and macroce-
phaly with an OFC of 54.1 cm (>98th percentile).
Subject 7 is an 11-year-old Dutch male who carries a
de novo c.1411G>A, p.Val471Ile missense change in RERE
that was estimated to be possibly damaging by PolyPhen-2
and disease causing by MutationTaster. He was also found
to have a compound heterozygous pair of mutations
in fibrous sheath interacting protein 2 (FSIP2 [MIM:
615796]): c.2602del, p.Ser868Hfs*12 and c.4583C>G,
p.Thr1528Arg (GenBank: NM_173651.2). The c.2602del
deletion is inherited from the father, and the c.4583C>G
missensemutation is inherited from themother and is a pre-
viously reported variant, rs192957612. This gene encodes
for a protein localized to the spermflagellumand is not asso-
ciated with any known human disease.26 The subject was
born prematurely at 34 weeks of gestation and weighed
2.24 kg (~5th percentile). This twin pregnancy was compli-
cated by maternal hypertension for which the mother
used medication. The subject has an older sister who is
healthy, but his twin sister was recently diagnosed with
KBG syndrome caused by a de novo c.3382_3383delGA,
p.Asp1128Glnfs*41 (GenBank: NM_001256182.1) change
in ankyrin repeat domain-containing protein 11 (ANKRD11
[MIM: 611192]), which was not found in this individual.27
His clinical features include developmental delay, hypoto-
nia, ADHD, mild intellectual disability, growth retardation,
dysmorphic features, and a cleft lip. A brain MRI obtained
at 7 years, 9 months of age showed an abnormal corpus
callosum with blunting of the rostrum, a small anterior
commissure, and diminished white matter volume.
Subject 8 is a 10-year-old male of European descent who
carries a c.1104delA, p.Leu369Cysfs*16 change in RERE.
This variant was not present in his mother, but a paternal
DNA sample could not be obtained for testing. Because
this change occurs in the last nucleotide of the 9th of 21
RERE coding exons, it might trigger nonsense-mediated
mRNA decay. Pregnancy was complicated by anemia,
a vaginal infection, and maternal smoking and alcohol016
Table 2. Overlapping Features Seen in Our Subjects, Individuals with Isolated 1p36 Deletions that Include RERE, and Zebrafish and Mice
Models
Phenotype
Subjects 1–10
Documented
with Phenotype
(% and No.)
Individuals with Isolated
1p36 Deletions Involving
RERE Documented with
Phenotype (% and No.)
Related Phenotype
Documented
in Rerea-Deficient
Zebrafish?13,17
Related Phenotype
Documented in
RERE-Deficient Mice?14,15
Neurologic problems 100% (10/10) 97% (30/31) no no
CNS anomalies 88% (7/8) 29% (9/31) no yes
Ophthalmologic abnormalities 40% (4/10) 42% (13/31) yes yes
Hearing loss 10% (1/10) 26% (8/31) yes yes
Orofacial clefting 10% (1/10) 16% (5/31) no no
Congenital heart defects 40% (4/10) 71% (22/31) no yes
Genitourinary anomalies 50% (5/10) 13% (4/31) no yesconsumption until eight weeks of gestation, when the preg-
nancywas recognized.Hewas born prematurely at 36weeks
of gestation. His clinical features included fine motor and
speech delay, autism spectrum disorder, and dysmorphic
features. A brain MRI ordered for developmental delay was
normal.
Subject 9 is a 7-year-old Dutch male who carries a
de novo c.2249_2270dup, p.Thr758Serfs*36 frameshift
change in RERE. This mutation was predicted to be disease
causing byMutationTaster. Pertinent findings in his family
history include a younger sister with autism, a paternal un-
cle who died of Duchenne muscular dystrophy, and a sec-
ond paternal uncle who died of acute heart failure at 20
years of age. Clinical features include severe speech and
language delay, intellectual disability, autism, dysmorphic
features, and a VSD. He has macrocephaly and an OFC of
57.3 cm (>99th percentile) at 6 years, 10 months of age.
However, this might be familial given that his mother’s
OFC is 59.7 cm (þ 2.5 SD).
While investigating the genetic causesof autism spectrum
disorder in a large cohort, Krumm et al. identified a 14-year-
old non-Hispanic female (subject 11654.p1) with autism
spectrum disorder who carried a de novo c.2278C>T,
p.Gln760* change in RERE.18 This mutation was estimated
to be disease causing by MutationTaster. Here, we refer to
her as subject 10. Her clinical features include autism spec-
trum disorder, sleep apnea, and nocturnal enuresis.
All of the subjects presented here have neurodevelop-
mental disorders—intellectual disability, developmental
delay, and/or autism (Table 2, Table S2). Recurrent neuro-
logical abnormalities reported in these subjects include
seizures, hypotonia, behavioral problems, ADHD, and
problems with feeding and swallowing. Brain anomalies
were documented in 88% (7/8) of subjects who had an
MRI and included abnormalities and/or thinning of the
corpus callosum (6/8, or 75%), diminished white matter
volume (6/8, or 75%), abnormal cerebellar vermis (4/8, or
50%), and ventriculomegaly (3/8, or 38%). Structural eye
defects were seen in 40% (4/10) of subjects and included
coloboma, optic atrophy and/or hypoplasia, microphthal-
mia, Peter anomaly, iris anomalies, and blepharophimosis.The AmCongenital heart defects were seen in 40% (4/10) of sub-
jects, and VSDs were the most common defect. Genitouri-
nary defects were seen in 50% (5/10), and vesicoureteral
reflux was documented in 30% (3/10) of subjects.
In addition to these examples of extra-neuronal organ
involvement, a variety of dysmorphic features were also
observed in our subjects (Table S2), including some fea-
tures previously associated with deletions of the proximal
1p36 critical region, such as frontal bossing, low-set, poste-
riorly rotated ears, epicanthic folds, anteverted nares, and
broad eyebrows (Figure 1).9 Our cohort also demonstrates
a variety of growth patterns—some subjects have short
stature (3/9, or 33%) or microcephaly (2/9, or 22%),
whereas others have tall stature (2/9, or 22%) or macroce-
phaly (2/9, or 22%). This suggests that physicians should
not rely heavily on the identification of a characteristic
constellation of physical features but rather on a grouping
of medical conditions, such as brain, eye, and cardiac
developmental defects, when considering the possible
diagnosis of an RERE-related disorder.
To determine the subset of 1p36 deletion phenotypes
that could possibly be explained by RERE haploinsuffi-
ciency, we compared the spectrum of structural birth de-
fects seen in our subjects to a cohort of 31 individuals
with isolated 1p36 deletions involving RERE (Table 2, Table
S1, Table S3, and Figure S1). These individuals were either
previously described in the literature or provided informed
consent and were enrolled in an institutional-review-
board-approved research study.9,16,28–33 In all cases, the
procedures followed were in accordance with the ethical
standards of the institution’s committee on human
research and were in keeping with national standards.
Within this cohort, 24 individuals carried larger terminal
or interstitial deletions that included all or part of both
the distal and proximal 1p36 deletion critical regions,
and seven individuals carried interstitial 1p36 deletions
that did not include the distal critical region (Figure S1).
We found that the majority of recurrent neurologic,
ophthalmologic, cardiac, and gastrointestinal pheno-
types seen our subjects were also seen in individuals in
the 1p36 deletion cohort. Overlap was also seen forerican Journal of Human Genetics 98, 963–970, May 5, 2016 967
Figure 2. RERE-Deficient Rereom/eyes3
Mice and Embryos Have Ventriculome-
galy, Microphthalmia, and Coloboma
(A and B) Representative cresyl-violet-
stained sagittal brain sections from a
wild-type mouse (A) and its Rereom/eyes3
littermate (B) show enlargement of the
lateral ventricles (black arrows). Ventricu-
lomegaly was seen in 3/3 Rereom/eyes3 adult
mice harvested between 5 and 10 months
of age. Scale bar represents 200 mm.
(C–F) Representative eyes from wild-type
embryos harvested at E13.5 (C) and
E17.5 (E) and their Rereom/eyes3 littermates
(D and F) demonstrate microphthalmia
and incomplete closure of the optic fissure
(white arrows in D and F). Failure of closure
was seen in 8/10 (80%) of Rereom/eyes3 eyes
examined at E13.5 and in 6/6 (100%) of
Rereom/eyes3 eyes examined at E17.5. Scale
bar represents 0.5 mm (C and D) or 1 mm
(E and F).sensorineural hearing loss, cleft lip, duodenal atresia,
cryptorchidism, hip dysplasia, and scoliosis, all of which
were identified in only one of our subjects. This overlap
suggests that haploinsufficiency of RERE might also be
sufficient to cause these additional phenotypes.
The phenotypic overlap between Rerea-deficient zebra-
fish and RERE-deficient mice and our subjects provides
further evidence that the deleterious sequence changes
observed in RERE are the cause of many of the phenotypes
observed in our subjects. This overlap also suggests that
these animals represent useful models in which to study
RERE’s role in the development of many organ systems
(Table 2). Specifically, we note that zebrafish carrying
homozygous mutations in rerea—the zebrafish homolog of
RERE—havemicrophthalmia, inconsistent startle response,
and decreased microphonic potentials.13,17 This provides
further evidence that changes in RERE are likely to be
responsible for the eye anomalies and sensorineural hearing
loss seen in our subjects.
Mice that are compound heterozygous for an Rere-null
allele (om) and a hypomorphic allele (eyes3) have an even
greater phenotypic overlap with our subjects. We have pre-
viously shown that thesemice havemicrophthalmia, optic
nerve hypoplasia, sensorineural hearing loss, congenital
heart defects, and post-natal growth deficiency.14 They
also have abnormal brain development including a
reduced brain size and weight, decreased numbers of
NeuN-positive hippocampal neurons, cerebellar foliation
defects, and delayed Purkinje cell maturation and migra-
tion in the cerebellum.14,15
Ventriculomegaly is seen in 38% (3/8) of our subjects. To
determine whether Rereom/eyes3 mice also have ventriculo-
megaly, we compared cresyl-violet-stained sagittal brain
sections from adult Rereom/eyes3 mice and their wild-type
littermates. Obtaining large numbers of Rereom/eyes3 mice
for study is difficult because only a small fraction live
into adulthood.14 However, in the three adult Rereom/eyes3
brains examined, all had enlarged lateral ventricles in com-968 The American Journal of Human Genetics 98, 963–970, May 5, 2parison to those of their littermate controls (Figures 2A and
2B). Given that 20% (2/10) of our subjects have colobo-
mas, we also looked for evidence of incomplete closure of
the optic fissure—a precursor to the development of colo-
boma—in Rereom/eyes3 embryos. Although the optic fissures
of wild-type mice close between embryonic days 11 (E11)
and E13, we found incomplete closure of the optic fissure
in 80% (8/10) of Rereom/eyes3 eyes examined at E13.5 and
100% (6/6) of the Rereom/eyes3 eyes examined at E17.5 (Fig-
ures 2C–2F).34 In contrast, the optic fissures of all wild-type
control littermates were closed at these time points.
Phenotype-genotype correlations are often not possible
to discern with a cohort of ten individuals, given that
genetic and non-genetic influences outside of the gene
can also affect the development of the final phenotype.
However, we have observed a partial association between
missense mutations in the atrophin 1 domain and clinical
severity. Thus, subjects 1–3 and subject 5, all of whomhave
missense mutations in this domain, have anatomic abnor-
malities of both the eye and brain. Subjects 1–3 all have
VSDs. Subjects 3–5 all have vesicoureteral reflux, and sub-
jects 1 and 2 present with other genitourinary malforma-
tions (Table S1). However, it is also possible that the pheno-
typic differences seen between subjects are due to the
effects of other genetic, epigenetic, environmental, and/
or stochastic factors. This hypothesis is supported by sub-
jects 4 and 5 whose missense mutations in RERE result in
the same amino acid change. Although they share many
phenotypes in common—intellectual disability, develop-
mental delay, seizures, abnormal and/or thin corpora
callosa, abnormal cerebellar vermis, vesicoureteral reflux,
deep-set eyes, and abnormal ears—they have other features
that are discordant. This hypothesis is also consistent with
the phenotypic variation seen in RERE-deficient mice on
different genetic backgrounds.14
RERE has previously been shown to positively regulate
retinoic acid signaling during somite development.11 Per-
turbations of retinoic acid signaling could also be the016
underlying cause of RERE deficiency’s effects on eye and
heart development. We note that autosomal-recessive
mutations in stimulated by retinoic acid 6 (STRA6
[MIM: 610745])—which encodes a transmembrane pro-
tein that transports retinol into cells—have been shown
to cause microphthalmia, isolated with colobomas 8
(MIM: 601186), and microphthalmia, syndromic 9
(MIM: 601186), also known as Matthew-Wood syndrome.
This syndrome is characterized by congenital heart defects
and eye anomalies—microphthalmia and coloboma—that
are similar to those seen in subjects 1 and 2.35–37 Similarly,
recessive loss-of-function mutations in aldehyde dehydro-
genase 1 family, members A3 (ALDH1A3 [MIM: 600463]),
which encodes an enzyme that converts retinaldehyde to
retinoic acid, cause microphthalmia, isolated 8 (MIM:
615113).38
In conclusion, we have shown that mutations in RERE
cause an autosomal-dominant genetic syndrome charac-
terized by neurodevelopmental defects, hypotonia, sei-
zures, behavioral problems, structural CNS anomalies—
abnormalities and/or thinning of the corpus callosum,
diminished white matter volume, abnormal cerebellar
vermis, and ventriculomegaly—ophthalmologic anoma-
lies, congenital heart defects, and genitourinary abnor-
malities. Many of these phenotypes are seen in individ-
uals with proximal 1p36 deletions that include RERE.
This suggests that haploinsufficiency of RERE might be
sufficient to cause many of the phenotypes associated
with proximal 1p36 deletions. These phenotypes are
also recapitulated in RERE-deficient zebrafish and mice,
which might serve as effective models for elucidating
the molecular mechanisms by which RERE acts in various
organ systems.Supplemental Data
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